17 results about "Healthy donor" patented technology

Provided is a technique for preparing universal DNT cells. The raw materials for preparation are derived from'white filtering residues' after white filtering treatment is carried out to avoid blood transfusion adverse reactions, and the DNT cells extracted from the white filtering residues can be a mixed culture of one or more healthy donors. The universal DNT cell obtained by using the method provided by the invention has the characteristics of high yield, high purity, high in-vitro tumor killing activity, suitability for large-scale production and the like. The initial raw material can be fresh cells or re-thawed cells after cryopreservation, the raw material source bottleneck of large-scale preparation of cell drugs is fundamentally solved, the value of leukocytes filtered out in the production process of blood products is re-excavated, and great medical value and commercial application prospects are achieved.

The present invention relates to modified T cells and methods of making and using the same. Specifically, disclosed herein are modified primary human T cells, and populations thereof, comprising a genome in which the CTLA4, PD1, TCRA, TCRB, and / or B2M genes have been edited to produce off-the-shelf universal CAR T cells from allogeneic healthy donors, the off-the-shelf universal CAR T cells can be administered to any patient while reducing or eliminating the risk of immunological rejection or graft versus host disease, and are not susceptible to T cell inhibition; and methods for allogeneic administration of the cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need thereof.

This invention relates to the application of mitochondrial formulations in the preparation of drugs for treating chronic obstructive pulmonary disease (COPD). The mitochondrial formulations contain active mitochondria isolated from healthy donor cells, with a particle size of 400–1000 nm, possessing normal mitochondrial membrane potential and ATP generation function, and capable of being internalized by mammalian COPD lung epithelial cells. In vitro cell experiments have confirmed that this mitochondrial formulation can repair CSE-induced mitochondrial dysfunction in lung epithelial cells, inhibit mPTP opening, reduce mtDNA leakage into the cytoplasm, thereby blocking the activation of the cGAS-STING signaling pathway and reducing the release of inflammatory factors such as IL-1β and TNF-α. In vivo experiments in COPD mouse models show that tail vein injection of the mitochondrial formulation can effectively accumulate in lung tissue, significantly improving lung pathological changes such as emphysema and collagen fiber deposition in model mice. This invention provides a novel strategy for COPD treatment based on repairing mitochondrial function and intervening in inflammatory signaling pathways.

The present invention involves the use of Caspase-1 inhibitors for treating ineffective erythropoiesis in patients with sickle cell disease (SCA). It highlights increased levels of IL-18 positive cells and Caspase-1 activity in hematopoietic stem cells (HSCs) of SCA patients compared to healthy donors. The invention demonstrates that treatment with a Caspase-1 inhibitor reduces this activity, suggesting its potential therapeutic benefit.

The invention discloses a microbial freeze-drying embedding method based on a pH-triggered phase change mechanism. The method comprises the following steps: step 1, preparing a zein solution: dissolving zein into a sodium hydroxide solution; step 2, preparing a bacterial suspension: taking fresh excrement of a healthy donor as a raw material, diluting with normal saline, uniformly stirring and mixing, and filtering with a multi-stage filter screen to obtain the bacterial suspension; 3, preparing an intestinal flora freeze-drying protective agent: dissolving lactose, maltotriose, mannitol, trehalose and antifreeze protein in normal saline according to a ratio, and sterilizing for later use; step 4, constructing a composite system: centrifugally washing the bacterial suspension, adding a freeze-drying protective agent, uniformly mixing in a vortex manner, adding a zein solution in proportion, and sufficiently and uniformly mixing; and step 5, freeze-drying treatment: performing vacuum freeze-drying on the composite system to form a compact hydrophobic protective layer, thereby obtaining the freeze-dried intestinal flora powder. According to the invention, the pH response characteristic of the protein is coupled with a freeze-drying process, so that efficient embedding protection of intestinal flora is realized.

The invention provides a targeting exosome for hair regeneration and a preparation method thereof. The method comprises the following steps: separating dermal mastoid cells with a cell marker CD133 from a hair follicle strain of a healthy donor, and culturing the dermal mastoid cells in a laboratory conforming to a Taiwan GTP cell preparation factory domain in China in a heterologous and serum-free environment. Then, a culture solution containing exosomes is collected from the cell culture solution, and the multiple exosomes have surface markers such as CD9, CD63 and CD81; and finally, separating, purifying and concentrating the exosome from the culture solution by utilizing a tangential flow filtration system method or a size exclusion chromatography method and other technologies to obtain the final targeting exosome freeze-dried powder product. The invention also provides a liquid hair growth preparation prepared from the exosome product.

The invention relates to a method for rapidly preparing exosomes by using human peripheral blood. In one aspect, the method for preparing plasma exosomes from peripheral blood comprises the following steps: (1) rapidly separating plasma components of the peripheral blood obtained from healthy donors or non-specific disease patients by using a differential centrifugation method; (2) performing thermal inactivation to remove a complement system in the plasma; (3) gradually removing impurities (such as substances including protein, polypeptide, fibrinogen and the like) in the plasma by a differential centrifugation method; and (4) precipitating the exosome component in the plasma by a PEG6000 method, and washing the precipitate to obtain the exosome. The invention further relates to the plasma exosome prepared from peripheral blood, the maximum value of particle size distribution of the plasma exosome is within the range of 80-200 nm, the positive rate of CD9-PE is larger than 70%, and the positive rate of CD81-PE is larger than 80%. The method disclosed by the invention can be used for rapidly and efficiently obtaining the exosome from the human peripheral blood.

The present invention relates to methods and compositions for generating and using myoblast chimeric cells (MCCs) for treating a muscle disease, such as muscular dystrophy, where the MCCs are composed of a myoblast derived from a patient with muscle disease (MD) and a myoblast from a donor without the MD (e.g., a healthy donor). In certain embodiments, cell fusion methods are performed using 2-4, or 5, times passaged myoblasts from the MD and donor subject, and / or polyethylene glycol 0.5-1.5 g / ml. In other embodiments, the MCCs created by fusion are passaged 1-5 times before use, and are passaged at 60-80% confluency. In further embodiments, the myoblasts and / or MCCs are tested at any stage during the process for less than 5-10% CD34 and / or CD45 expression, and / or greater than 50-70% CD56 and / or CD90 expression.

The present application relates to the application of mitochondrial transplantation preparation in the preparation of a drug for treating non-alcoholic fatty liver disease, wherein the mitochondrial transplantation preparation comprises active mitochondria isolated from healthy donor cells, and has normal membrane potential and mitochondrial respiratory function. In vivo experiments on a non-alcoholic fatty liver mouse model prove that tail vein injection of the mitochondrial transplantation preparation of the present application can effectively reduce the weight of the mouse, improve the fatty liver condition of the mouse, reduce the accumulation of fat in the liver tissue, and at the same time restore the abnormal liver function of the non-alcoholic fatty liver mouse.

The application belongs to the technical field of medicine, and particularly relates to a CAR-gammadelta T cell targeting GP350 and a preparation method and application thereof. The application provides an antibody or antigen binding fragment thereof targeting GP350. The GP350-targeting antibody screened is used as an antigen binding domain to construct a chimeric antigen receptor, and a gammadelta T cell isolated from peripheral blood of a healthy donor is used to prepare a CAR-gammadelta T cell targeting GP350. In-vivo and in-vitro experiments show that the CAR-gammadelta T cell targeting GP350 has obvious killing activity on an EBV-positive nasopharyngeal carcinoma cell (GP350 + ). The application can be applied to the diagnosis of EBV-positive diseases, and has a broad prospect in the preparation of products for detecting, preventing and / or treating GP350-positive tumors.

The invention belongs to the technical field of cellular immunity, and particularly relates to a DC-CIK cell culture method based on an HBV protective antibody positive healthy donor and application, the cell culture method comprises the following steps: selecting HBsAg negative and anti-HBs antibody positive healthy donor peripheral blood mononuclear cells, loading a dendritic cell (DC) by using a mixed antigen of HBcAg and HBsAg, and culturing the DC-CIK cell by using a cell culture medium. And co-culturing the DC cells and cytokine-induced killer cells (CIK) to finally obtain the allogenic DC-CIK cells. According to the invention, DC cells of healthy donors and CIK cells are co-cultured to obtain allogenic DC-CIK cells, an HBcAg and HBsAg mixed antigen loading technology is adopted to significantly improve the antigen presentation capability of the DC cells, an optimized culture system enhances the targeting killing function of the cells, and the HBsAg clearance rate and the cccDNA inhibition rate can be effectively improved in combination with nucleoside analogue treatment, so that the DC-CIK cells can be used for preparing the DC-CIK cells. The synergistic breakthrough of efficient virus removal, immune function reconstruction and low recurrence rate in hepatitis B treatment is realized.

The present application belongs to the technical field of biological medicine, and particularly relates to an oral preparation of lipoxygenase of a healthy donor treatment type intestinal flora exosome package and a preparation method and application thereof. The oral preparation of lipoxygenase of a healthy donor treatment type intestinal flora exosome package comprises 0.18-0.78wt% lipoxygenase, 0.24-0.48wt% fucoidan, 1.0-2.0wt% tetrahydropyrimidine and a healthy donor treatment type intestinal flora exosome supplementing to 100% according to weight percentage. The present application adopts an ultrasonic method to prepare the lipoxygenase of a healthy donor treatment type intestinal flora exosome package, uses the treatment type intestinal flora exosome as a natural medicine carrier, successfully solves the technical problem of low oral bioavailability of lipoxygenase, and provides a new effective means for enhancing immunity and preventing and treating tumors.

A method for preparing targeted dermal papilla cell-derived exosomes is provided. The method involves first isolating a plurality of dermal papilla cells (DPCs) with a cell surface marker CD133 from the hair follicles of a healthy donor, in a xeno-free and serum-free environment in GTP lab in Taiwan (or GMP lab in international). Subsequently, a cell culture medium containing a plurality of exosomes is collected, wherein these exosomes possess surface markers such as CD9, CD63, and CD81. Finally, the exosomes are isolated, concentrated, and purified from the culture medium using techniques such as tangential flow filtration system (TFF system) or size exclusion chromatography, thereby obtaining the final targeted exosome lyophilized product. A liquid hair growth formulation formulated with this exosome product is also provided.

This application discloses the application of mitochondrial preparations pretreated with lipoic acid and NMN in the prevention and treatment of doxorubicin-induced myocardial injury. This application pre-treats healthy donors with lipoic acid and NMN to obtain functional myocardial mitochondria with significantly enhanced antioxidant capacity and energy metabolism efficiency. These pre-treated mitochondria are then directly injected in situ into the doxorubicin-damaged myocardium, achieving a synergistic effect of "pretreatment enhancement + local transplantation." This results in significantly better outcomes than conventional mitochondrial transplantation or systemic drug administration alone in terms of efficient colonization and functional replacement. By organically combining donor pretreatment with recipient local transplantation, this application effectively overcomes the shortcomings of existing technologies, such as poor targeting and insufficient efficacy, providing a highly efficient, targeted, and synergistic new treatment strategy for doxorubicin-induced acute myocardial injury.

Despite the notion that human CD8+ T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (TID), none of their target epitopes has been demonstrated to be naturally processed and presented by β cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased β-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known β-cell antigens and several insulin granule proteins. Secretogranin V (SCG5 / 7B2) was identified as a novel β-cell antigen, which was processed into HLA-A2- and HLA-A3-restricted epitopes recognized by circulating naïve CD8+ T cells in type 1 diabetic and healthy donors. HLA-A2-bound neo-epitopes were also represented and originated from an alternative SCG5-009 mRNA splice isoform. Accordingly, the present invention relates to antigenic peptides derived from secretogranin V and uses thereof for the diagnosis and treatment of T1D.

The invention discloses a culture medium and a culture method for culturing human intestinal flora in vitro, every 1000g of the culture medium contains 5-20g of casein tryptone, 1-10g of beef extract, 1-10g of soybean oligosaccharide, 0.1-1g of monopotassium phosphate, 1-15g of sodium chloride, 0.5-5mg of hemin, 1-5g of cysteine hydrochloric acid, 0.5-2g of cholate, 20-100g of microcrystalline cellulose and 1-5g of agar powder, water is added to fix the volume to 1000mL, and the pH value is adjusted to 6.0-7.5. And after high-temperature steam sterilization, cooling to 40 DEG C, adding 0.5-5 / 1000 (V / V) serum, and uniformly mixing. The invention provides a culture medium and a culture method capable of culturing flora growth in human excrement twice through passage. In-vitro culture similar to intestinal flora characteristics of healthy donors is successfully realized, so that an ideal intestinal bacteria product is provided for intestinal bacteria transplantation treatment.

The application discloses a research method for tumor cell influence mechanism of monocyte remodeling based on bone marrow inflammatory microenvironment, and relates to the technical field of tumor treatment; and comprises the following steps: S1, providing bone marrow plasma from a classic myeloproliferative neoplasm patient; S2, placing primary CD14+ monocytes from a healthy donor in an in-vitro culture system containing the bone marrow plasma, inducing phenotype remodeling of the monocytes, and obtaining the remodeling monocytes. The application establishes CD163+CD206+ double-positive remodeling monocytes as a new target for MPN treatment; through comparison experiments of direct co-culture and indirect co-culture by Transwell, it is confirmed that the promotion effect of the remodeling monocytes on HEL cell proliferation strictly depends on physical contact between cells, rather than soluble secreted factors; and the application provides a theoretical basis for developing new antibody drugs or small molecule inhibitors for blocking cell-cell interaction.